Skip to main content
. 2013 Feb 4;55(9):2151–2160. doi: 10.3109/10428194.2013.856008

Figure 1.

Figure 1.

Tumor growth inhibition (TGI) and tumor-free animals in s.c. Z138 MCL model following 10 mg/kg obinutuzumab (GA101) or rituximab. IQR, interquartile range. Treatment of the s.c. Z138 MCL model with 10 mg/kg obinutuzumab or rituximab (q7d × 4, i.v.) was initiated when tumor reached an average size of 214 mm3. (A) TGI until day 48, (B) number of tumor-free animals until day 56.